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Abstract
A new model with a variable size of random effect is introduced for the
meta-analysis of 2 × 2 tables. The random-effects parameter has a simple
interpretation in terms of sample size and offers a new measure of hetero-
geneity.
1. Introduction
The focus of this article is binary-data meta-analysis applied in medicine
and epidemiology, and the language of those subjects is used. However, the
results here apply also to meta-analysis generally. Beyond medicine and
epidemiology, there is a very wide range of application areas, e.g. education.
By far the most common trial design for binary data is a parallel study,
in which one patient group receives treatment A, and the other receives
treatment B. Often but not always, ‘treatment A’ will be a placebo. An
event (some measure of recovery or the reverse, such as death) occurs to some
members of each group. There are usually no individual patient covariates
such as age or disease duration, so the results can be summarized in a 2× 2
table. In epidemiological studies, typically group A is the control group,
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and group B has been exposed to some hazard.
In a meta-analysis we seek to estimate the ‘treatment effect’ θ and its
standard error from a number of such 2 × 2 tables, each one giving the
results of a study that a systematic review has found to be of acceptable
quality. One major problem is that studies often disagree by more than
their quoted statistical errors would indicate. This disagreement may arise
in medicine because of differing patient mixes among the various studies,
varying operational procedures, or use of a wrong model of treatment effect
by the analyst. This problem appears in nearly half of binary-data meta-
analyses and is even more prevalent for continuous outcomes (Alba et al,
2016); the random effect is larger for ‘softer’ outcomes and lowest for ‘hard’
outcomes such as mortality (Turner et al, 2012). The Higgins et al (2003) I2
statistic is often used to give a measure of this extra variability (for caveats,
see Borenstein et al 2017).
A standard approach is to model the excess variability by assuming that
the observable treatment effect varies from study to study, so that the ith
study ‘sees’ θi = θ + ǫi, where ǫi ∼ N [0, τ2]. In this paper a modified form
for the random effect is introduced, in which rather than simply assuming
that the effective value of θ varies from study to study, it is considered that
this variation is induced by the probabilities of the event occurring under
treatments A and B varying randomly between studies, so that the ith
study has effective event probabilities that differ from the correct values,
for the reasons given. Modelling this variation in probabilities using the
beta distribution rather than modelling the variation in θi directly gives a
slightly different form for the random effect, in which its scale is geared to
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the variance that θˆi would have for a constant sample size, say unity, in each
group.
Note that if the treatment A and B event probabilities do not vary much
from study to study, it does not matter which model of treatment effect
is used, and also the random effects model proposed here and conventional
models would give similar fits to data and give rise to similar conclusions.
However, these probabilities usually do vary appreciably across studies.
The new random-effects submodel is derived, some examples are given,
and the paper ends with some brief conclusions.
2. The new model
2.1. Some notation
Let there be n studies; table 1 gives notation for the observed data from
a study. Study suffices will often be suppressed for clarity.
Let p be the probability of an event for treatment A (often control/placebo)
and q the corresponding probability for treatment B. Let the treatment ef-
fect be θ = g(q, p). The currently-used treatment effects can all be written
as θ = T (q)− T (p), for some monotonic function T , but this simplification
is not needed here. Thus the widely-used log-odds ratio is
θ = ln(q/(1 − q))− ln(p/(1 − p)) = ln(q(1− p)/p(1 − q)). (1)
The methodology is exemplified using the log-odds ratio throughout, but is
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quite general. Two-stage models give
θˆi = g(qˆi, pˆi) (2)
from the ith study, where θˆi is assumed to be approximately normally dis-
tributed with mean θ. Sample sizes are taken as Nq, Np respectively.
2.2. Derivation of the model
The task is to find the variance of θˆ, which is assumed to be approx-
imately normally distributed. Besides sampling error, the variance must
include the random errors in P and Q; we use P to show the method,
and results are similar for Q. For small changes δp, δq we have that δθ ≃
(∂g/∂p)δp+(∂g/∂q)δq, and assuming that δp, δq are independent, the delta
method (e.g. Oehlert, 1992) gives
var(θˆ) ≃ {(∂g/∂p)}2var(P ) + {(∂g/∂q)}2var(Q).
Taking Np, Nq as fixed, assume that the effective probability of an event is
a random variable from some distribution. The beta distribution, as the
conjugate prior for the binomial distribution, is a natural choice here. With
parameters α, β the mean is p = α/(α + β). Then using the notation in
table 1, n11 is the realization of a beta-binomial random variate (see e.g.
Prentice, 1986), with mean Npα/(α + β), variance
var(n11) =
Npαβ(α+ β +Np)
(α+ β)2(α+ β + 1)
. (3)
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Reparameterizing, one parameter, the random effect size, is taken as ρ =
1/(α + β + 1), and this is also the intra-study correlation. The method of
moments gives pˆ = n11/Np = ραˆ/(1 − ρ). Hence βˆ = (1 − ρ)(1 − pˆ)/ρ, and
so from (3) the estimated variance of pˆ is
var(n11/Np) ≃ pˆ(1− pˆ){1/Np + (1− 1/Np)ρ}. (4)
Hence finally
var(θˆ) ≃ {(∂g/∂p)}2 pˆ(1−pˆ){1/Np+(1−1/Np)ρ}+{(∂g/∂q)}2 qˆ(1−qˆ){1/Nq+(1−1/Nq)ρ},
(5)
which can be written for the ith study
var(θˆi) = σ
2
i + viρ.
The parameter ρ also has the meaning that α + β = (1 − ρ)/ρ is the
notional or effective sample size per group for the inter-study variation in
θi. The practical application of this is that there is little point in new
studies having much larger sample size than ρ−1. The statistic ρˆ, expressed
as a percentage, is a new measure of heterogeneity, not related to statistical
significance as is I2. For example, as sample size per study increases, I2 will
tend to 100%, but ρˆ will remain constant. Borenstein et al (2017) stress that
I2 is not ‘an absolute measure of heterogeneity’ although it is often taken
as such; ρˆ is an absolute measure.
This model has the implication that the size of random error for a study
is geared to the sizes of pˆ and qˆ; for values of pˆ, qˆ, giving a tiny variance,
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the random effect variance is similarly tiny. Thus for the log-odds ratio
σ2i =
1
qˆ(1−qˆ)Nq
+ 1pˆ(1−pˆ)Np , so that the extra variance ρ{ 1qˆ(1−qˆ) + 1pˆ(1−pˆ)} is
smallest when pˆ, qˆ = 1/2. This is the difference from the standard model,
where the size of random error is constant.
Note that for the arc-sine transformation, designed to stabilize variance,
θ = sin−1(
√
q) − sin−1(√p), we have that vi = 1/2, so the new method
reduces to the old. For risk difference θ = q − p we have that vi = pˆ(1 −
pˆ)+ qˆ(1− qˆ). The size of the random effect is now greatest where pˆ, qˆ ≃ 1/2.
Also, if Nq = Np is constant for all trials, the new method amounts to a
multiplicative rescaling of variance, like the methods used in particle physics
(Baker and Jackson, 2013 )
2.3. Changes to the DerSimonian and Laird and Mandel-Paule procedures
The DerSimonian and Laird (1986) method for random-effects meta-
analysis has been very popular in the life sciences. Writing wi = 1/σ
2
i ,
the sum of squares Q =
∑n
i=1(θˆi − θ¯)2/σ2i (where θ¯ =
∑n
i=1wiθˆi/
∑n
i=1wi)
is equated to its expectation, under the assumption that θˆi has variance
σ2i + τ
2 = 1/w∗i . This yields the DSL estimator
τˆ2 = max{0, Q− (n− 1)∑n
i=1 wi −
∑n
i=1w
2
i /
∑n
i=1wi
},
where now θ is estimated as
∑n
i=1 w
∗
i θˆi/
∑n
i=1 w
∗
i with standard error (
∑n
i=1 w
∗
i )
−1/2.
We follow the same derivation, under the assumption that θˆi has variance
σ2i + viρ, which yields the estimator
ρˆ = max{0, Q− (n− 1)∑n
i=1 viwi −
∑n
i=1 viw
2
i /
∑n
i=1wi
},
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and σ2i + viρ = 1/w
∗
i , so that θ and its standard error are now estimated as
before.
The Mandel-Paule estimator (e.g. Hartung, Knapp and Sinha, 2008)
minimises Q(τ2) =
∑n
i=1
(θˆi−θ˜)2
σ2
i
+τ2
for θ˜, so that θ˜ =
∑n
i=1 θˆi/(σ
2
i
+τ2)
∑n
i=1 1/(σ
2
i
+τ2)
and es-
timates τ2 iteratively by setting Q = n − 1. It can be trivially changed
to Q(ρ) =
∑n
i=1
(θˆi−θ˜)
2
σ2
i
+viρ
, minimized for θ˜, and ρ then estimated by setting
Q(ρ) = n − 1. Hence the standard methods of meta-analysis can be easily
tweaked to make the adjustment recommended here.
2.4. Examples
Table 2 shows details of the 15 datasets used as examples. These were
datasets that were comparatively easily available, and some such as the
tuberculosis dataset are very well known and much studied.
The results are shown in table 3. A maximum likelihood fit for the
parameters θ and τ2 or ρ was done to evaluate the relative goodness of fit of
the conventional and proposed new model, but the estimates of treatment
effect θ shown with standard errors are derived using the DerSimonian and
Laird procedure, and the modified version of this. This was done rather
than quoting results from the maximum likelihood analysis, because the
DSL method is very widely used.
Of the 15 meta-analyses studied, 10 had higher likelihood with the new
method, 2 had lower likelihood (Eclamp and Resp), while 3 ( Lamo, Steroid
and Strep) fitted with random effect going to zero, so both methods gave
identical results. In two of these latter cases the results are shown, because
θˆ differed using the DSL method. In the 2 cases where the new method gave
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a worse fit, the decrease in log-likelihood was small, not more than 0.25.
However when the fit was better, the improvement could be much larger,
of the order of 2.0. This shows convincingly that the new method fits data
better. The estimates of treatment effect have smaller modulus in 11 cases,
and are larger in 4, big enough changes to make the new model of practical
interest. The maximum change was something like 15% of treatment effect.
The standard errors were always slightly smaller for the new method, which
is another advantage.
The random effect ρˆ estimated from the modified DerSimonian and Laird
method is also shown as a percentage. It correlates only weakly with the
I2 statistic, because I2, although a measure of heterogeneity, derives from a
measure of significance, whereas ρ is an absolute measure of heterogeneity.
3. Conclusions
A modification of the standard normal random effects model for 2 × 2
table data has been derived, where the size of the random effect is scaled
to the size of the variances for the event probabilities for treatments A and
B (at a fixed sample size). There is thus an effect on inference: a sample
treatment effect measure such as the log-odds ratio (1) has smallest variance
when pˆ ≃ 1/2, qˆ ≃ 1/2. The random effect will be smaller there, so that
studies where pˆ are small or large will have a larger random effect variance
ρ and so be downweighted. Thus the weighting accorded to the various
studies is altered. This model can be seen as the conversion of the beta-
binomial regression model mentioned by Kuss (2015) to a 2-stage model.
Hence the attractive properties of the beta-binomial model found by Kuss
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(2015) should carry over to the 2-stage model.
This modification of a familiar model gave slightly better fits to data
than the conventional model for most of the sample of datasets studied. It
can be used wherever random effects occur in binary-data meta-analysis,
e.g. in multivariate and network meta-analysis, in meta-regression, or in
diagnostic meta-analysis, where the diagnostic odds ratio (DOR) can be
given this type of random effect. Further experience with this model by
other workers is of course necessary, and its computation would require only
a small tweak of existing software.
A spin-off from this model is that the random-effects statistic ρˆ derived
in section 2.2 is more meaningful than the usual variance τ2, being a measure
of heterogeneity on a scale from 0 to 1, and having the second meaning that
the effective sample size for the random variation is ≃ 1/ρ. As pointed out
by Borenstein (2017), the familiar I2 statistic has the drawback that it is
not an absolute measure of heterogeneity.
For 1-stage meta-analyses, this model offers a computationally simple
method that often gives better fits to data, confirming the results of Kuss
(2015). This analysis is available in appendix A in the supplementary ma-
terial available online for this paper. Future work could be the comparison
of the adjusted model with the standard model for a much larger sample of
meta-analyses.
References
[1] Alba, A. C., Alexander, P. E., Chang, J., MacIsaac, J., DeFry, S. and
Guyatt, G. H. (2016). High statistical heterogeneity is more frequent in
10
meta-analysis of continuous than binary outcomes, Journal of Clinical
Epidemiology, 70, 129-135.
[2] Baker R. D., Jackson D. (2013). Meta-analysis inside and outside par-
ticle physics: two traditions that should converge? Research Synthesis
Methods 4, 109124.
[3] Borenstein, M., Higgins, J. P. T., Hedges, L. V. and Rothstein, H.
R. (2017). Basics of meta-analysis: I2 is not an absolute measure of
heterogeneity. Research Synthesis Methods, DOI: 10.1002/jrsm.1230
[4] Borenstein, M., Hedges, L. V., Higgins, J. P. T. and Rothstein, H. R.
(2009). Introduction to meta-analysis, Wiley, New York
[5] Chen D-G D, Peace KE (2013). Applied Meta-Analysis with R, Chap-
man and Hall/CRC.
[6] DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled
Clinical Trials 1986; 7: 177–188.
[7] Egger, M., Altman, D. G., Smith, G. D. (2001). Systematic Reviews in
Health Care 2e: Meta-analysis in Context, 2nd. ed., BMJ Publishing
Group, London
[8] Fergusson, D., Glass, K. C., Hutton, B., and Shapiro, S. (2005). Ran-
domized controlled trials of aprotinin in cardiac surgery: could clinical
equipoise have stopped the bleeding?. Clinical Trials, 2(3):218–229.
[9] Hartung, J., Knapp, G. and Sinha, B. K. (2008). Statistical meta-
analysis with applications, Wiley, New York.
11
[10] Higgins, J., Thompson, S. G., Deeks, J. J. and Altman, D. G. (2003).
measuring inconsistency in meta-analyses, British Medical Journal,
327, 557-560.
[11] Kuss, O. (2015). Statistical methods for meta-analyses including infor-
mation from studies without any events-add nothing to nothing and
succeed nevertheless. Statistics in Medicine, 34 (7), 1097-1116.
[12] Oehlert, G. W.. (1992) A note on the delta method, The American
Statistician, 46 (91), 27-29.
[13] Pani P. P., Trogu, E., Pacini M. and Maremmani, I. (2014). Anticonvul-
sants for alcohol dependence, Cochran Systematic Review CD008544,
analysis 1.1
[14] Prentice, R. L. (1986). Regression using an extended beta-binomial dis-
tribution,Journal of the American Statistical Association, 81, 321-327.
[15] Ramaratnam, S., Marson, A. G. and Baker, G.A. (2001). Lamotrig-
ine add-on for drug resistant partial epilepsy. Cochrane Database of
Systematic Reviews 2001, 3.
[16] Sharp, S. J., Thompson, S. G. and Altman, D. G. (1996). British Med-
ical Journal 313, 735–738.
[17] Sidik, K. and Jonkman, J. N. (2008). Estimation using non-central
hypergeometric distributions in combining tables. Journal of Statistical
Planning and Inference, 138 (12): 3993–4005.
12
[18] Turner, R. M., Omar, R. Z., Yang, M., Goldstein, H. and Thompson,
S. G. (2000). A multilevel framework for meta-analysis of clinical trials
with binary outcomes, Statistics in Medicine 19, 3417-3432.
[19] Turner,R. M., Davey, J., Clarke,M. J., Thompson, S. G. and Higgins,
J. P. T. (2012). Predicting the extent of heterogeneity in meta-analysis,
using empirical data from the Cochrane Database of Systematic Re-
views, International Journal of Epidemiology, 41, 818-827.
[20] Warn, D. E., Thompson, S. G. and Spiegelhalter, D. J., Bayesian
random-effects meta-analysis of trials with binary outcomes: methods
for the absolute risk difference and relative risk scales, Statistics in
Medicine (2002). 21, 1601–1623.
Tables
event↓,group→ Treatment A Treatment B
Yes n11 n12
No n21 n22
Total N1 or Np N2 or Nq
Table 1: Notation for 2 × 2 tables; columns are the group, rows the event, e.g. recovery
or death.
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Name Description Reference Studies
Amant Amantidine for influenza Higgins et al. [10] 8
Anti Anticonvulsants for alcoholism, dropouts Pani et al. [13] 17
Apro Aprotinin to reduce perioperative bleeding Fergusson [8] 64
Circum Circumcision and HIV prevalence Borenstein et al. [4] 33
Cis Cisapride for nonulcer dyspepsia Hartung et al. [9] 13
Eclamp Diuretics for pre-eclampsia Turner et al. [18] 9
Endo New surgical therapy for bleeding peptic ulcers Sidik and Jonkman [17] 41
Ibup Ibuprofen for post-operative pain Warn et al. [20] 46
Lamot Lamotrigine for drug-resistant partial epilepsy Ramaratnam et al. [15] 11
Resp Selective decontamination for RPI Turner et al. [18] 22
Sclero Endoscopic sclerotherapy for liver disease Sharp et al. [16] 19
Smoking Smoking cessation Baker & Jackson [2] 111
Steroid Steroids for reducing neonatal deaths Chen and Peace [5] 7
Strept Intravenous streptokinase in MI Egger et al. [7] 22
TB BCG vaccine for TB prevention Hartung et al. [9] 13
Table 2: Summary of the 15 datasets used in our empirical investigation. RPI denotes
respiratory tract infection and MI denotes myocardial infarction.
Name I2% −ℓ −ℓnew θˆ θˆnew 100ρˆ
Amant 47.0 1.207 0.888 -1.098 (.231) -1.011 (.208) 0.73
Anti 57.7 4.584 4.403 -0.144 (.197) -0.156 (.195) 3.13
Apro 44.0 19.814 19.501 -1.032 (.088) -1.006 (.086) 1.41
Circum 92.3 6.999 5.983 -0.513 (.150) -0.586 (.129) 3.11
Cis 71.2 7.547 7.503 1.491 (.308) 1.361 (.306) 7.98
Eclamp 70.8 1.222 1.421 -0.518 (.204) -0.425 (.181) 0.74
Endo 54.6 32.468 30.480 -0.997 (.189) -0.924 (.184) 0.56
Ibup 50.7 30.475 29.022 2.022 (.151) 1.797 (.140) 2.55
Lamo 0 0.530 0.530 0.950 (.167) 0.950 (.167) 0.00
Resp 63.8 8.406 8.658 -1.221 (.167) -1.153 (.163) 2.09
Sclero 56.2 3.266 2.675 -0.339 (.175) -0.333 (.173) 2.96
Smoking 26.3 -31.947 -32.354 0.567 (.0392) 0.562 (.0387) 0.20
Steroid 12.5 -0.3851 -0.3851 -0.6292 (.192) -0.616 (.190) 0.13
Strept 33.3 -7.431 -7.431 -0.245 (.0622) -0.247 ( .0621) 0.09
TB 95.3 1.3964 -0.5435 -0.856 (.225) -1.009 (.145) 0.18
Table 3: 2-stage meta-analysis results using standard and new methods for the log-odds
ratio. Minus the log-likelihood is shown, plus treatment effect estimates obtained using the
DerSimonian and Laird procedure, with standard errors in parentheses, and the random-
effect correlation ρˆ.
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